about
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action.Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies.Glucocorticoid receptor signalling activates YAP in breast cancer.Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells.Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1.Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer TherapyFc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity
P50
Q33804626-6B323B5D-0A44-4360-8C6B-11730DA1E194Q37224604-38800289-3F4E-4526-9A7B-B23E4A2BC4F1Q37598468-E5C836E3-5F89-49C2-A871-82B2C392F66BQ39383951-DC6DCD57-FAA6-412F-8E45-047F6D6A54A5Q41338135-C5C22C70-B912-4A49-BD88-D6F49E39B5E8Q42660162-D1EA43AD-3954-45F8-8E8F-8CFAF3FB1F6EQ91343355-27877147-DF84-4109-A2E8-A0663BD17235
P50
description
researcher
@en
wetenschapper
@nl
name
Elisa Cappuzzello
@en
Elisa Cappuzzello
@nl
type
label
Elisa Cappuzzello
@en
Elisa Cappuzzello
@nl
prefLabel
Elisa Cappuzzello
@en
Elisa Cappuzzello
@nl
P31
P496
0000-0001-6733-795X